Breast Cancer Coverage from Every Angle

Peter Schmid, MD, PhD, on The Future of Checkpoint Inhibitors in the Neoadjuvant Setting

Posted: Monday, September 30, 2019

Peter Schmid, MD, PhD, of Queen Mary University of London Barts Cancer Institute, discusses the clinical impact of findings from KEYNOTE-522 on pembrolizumab plus chemotherapy in terms of other checkpoint inhibitors being used to treat breast cancer in the neoadjuvant setting.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.